Advertisement

An unmet medical need vs. regulatory recommendations: how should we treat patients with hyperaldosteronism and advanced chronic kidney disease when surgery is not feasible?

  • 43 Accesses

This is a preview of subscription content, log in to check access.

Access options

Buy single article

Instant unlimited access to the full article PDF.

US$ 39.95

Price includes VAT for USA

Subscribe to journal

Immediate online access to all issues from 2019. Subscription will auto renew annually.

US$ 199

This is the net price. Taxes to be calculated in checkout.

References

  1. 1.

    Capelli I, Gasperoni L, Ruggeri M, Donati G, Baraldi O, Sorrenti G, Caletti MT, Aiello V, Cianciolo G, la Manna G (2019) New mineralocorticoid receptor antagonists: update on their use in chronic kidney disease and heart failure. J Nephrol:1–12. https://doi.org/10.1007/s40620-019-00600-7

  2. 2.

    Kolkhof P, Barfacker L (2017) 30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development. The Journal of endocrinology 234 (1):T125–T140

  3. 3.

    Danjuma MI, Mukherjee I, Makaronidis J, Osula S (2014) Converging indications of aldosterone antagonists (spironolactone and eplerenone): a narrative review of safety profiles. Curr Hypertens Rep 16(2):414. https://doi.org/10.1007/s11906-013-0414-8

  4. 4.

    Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341(10):709–717. https://doi.org/10.1056/NEJM199909023411001

  5. 5.

    Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH et al (2013) 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 62(16):e147–e239. https://doi.org/10.1016/j.jacc.2013.05.019

  6. 6.

    Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM et al (2017) 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation 136(6):e137–ee61. https://doi.org/10.1161/CIR.0000000000000509

  7. 7.

    Medicines.org.uk (2019) Spironolactone - summary of product characteristics (SPC) - (eMC). https://www.medicines.org.uk/emc/ingredient/36. Accessed 26 June 2019

  8. 8.

    Agencia Española de Medicamentos y Productos Sanitarios - AEMPS (2019) Espironolactona - Summary of Product Characteristics (SPC). https://cima.aemps.es/cima/publico/lista.html. Accessed 26 June 2019

  9. 9.

    Swedish Medical Products Agency (2019) Spironolakton -summary of product characteristics (SPC). https://lakemedelsverket.se/LMF/?q=Spironolakton&type=product. Accessed 27 June 2019

  10. 10.

    Agenzia Italiana del Farmaco - AIFA (2019) Luvion - Riassunto delle caratteristiche del prodotto. https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000913_024273_RCP.pdf&retry=0&sys=m0b1l3. Assessed 26 Aug 2019

  11. 11.

    Medicines Evaluation Board (2019) Spironolacton - summary of product characteristics (SPC) https://www.geneesmiddeleninformatiebank.nl/nl/. Accessed 30 June 2019

Download references

Author information

Correspondence to Ivana Mikačić.

Ethics declarations

Conflict of interest

The author declares that she has no conflict of interest.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

ESM 1

(DOCX 19.3 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Mikačić, I. An unmet medical need vs. regulatory recommendations: how should we treat patients with hyperaldosteronism and advanced chronic kidney disease when surgery is not feasible?. Eur J Clin Pharmacol 76, 131–132 (2020) doi:10.1007/s00228-019-02774-2

Download citation

Keywords

  • Hyperaldosteronism
  • Chronic kidney disease
  • Spironolactone
  • Eplerenone